3 results
Approved WMOCompleted
To compare the effect of semaglutide 1.0 mg once-weekly versus exenatide extended release (ER) 2.0 mg once-weekly on glycaemic control after 56 weeks of treatment.
Approved WMOCompleted
The objective of this study is to demonstrate the safety and effectiveness of the Hydrus Aqueous Implant for lowering IOP in patients with primary open-angle glaucoma (POAG) who are undergoing concurrent cataract surgery.
Approved WMOCompleted
To compare the effect of once-weekly dosing of two dose levels of semaglutide versus insulin glargine once-daily on glycaemic control after 30 weeks of treatment in insulin-naïve subjects with type 2 diabetes.